BME:ALMPharmaceuticals
Assessing Almirall (BME:ALM) Valuation After Dermatology Pipeline Updates And 2025 Guidance Reaffirmation
Almirall (BME:ALM) has drawn fresh investor attention after updating its medical dermatology pipeline at the J.P. Morgan Healthcare Conference and confirming 2025 sales guidance, alongside announcing a planned phase III Lebrikizumab study in nummular eczema.
See our latest analysis for Almirall.
Those R&D and guidance updates come after a year where Almirall’s share price showed modest short term momentum, including a 2.39% 1 day share price return. Longer term total shareholder returns of...